Biden to nominate tech critic Lina Khan as an FTC commissioner
Send a link to a friend
[March 23, 2021]
By Diane Bartz
WASHINGTON (Reuters) - U.S. President Joe
Biden intends to nominate Lina Khan, an antitrust researcher who has
focused her work on Big Tech's immense market power, to be a
commissioner on the Federal Trade Commission, the White House said
Monday.
Khan, who teaches at Columbia Law School, is highly respected by
progressive antitrust thinkers, who have pushed for tougher antitrust
laws or at least tougher enforcement of existing law.
Her nomination follows on the heels of the selection of fellow
progressive and Big Tech critic Tim Wu to join the National Economic
Council.
If confirmed, Khan will return to the FTC where she was a legal adviser
to Commissioner Rohit Chopra, Biden's pick to be director of the
Consumer Financial Protection Bureau.
Khan was on the staff of the House Judiciary Committee's antitrust
panel, which wrote a massive report last year that sharply criticized
the major tech companies, Amazon Inc, Apple Inc, Facebook Inc and
Alphabet Inc.
The FTC works with the Justice Department to enforce antitrust law and
investigates allegations of deceptive advertising.
[to top of second column]
|
While Senator Amy Klobuchar, who strongly favors antitrust
enforcement, welcomed her nomination, NetChoice, whose members
include Facebook and Google, opposed her as a "radical pick."
"She is more interested in subjectively changing antitrust law than
in analyzing and enforcing the law as it stands," said NetChoice
General Counsel Carl Szabo.
Khan's nomination comes as the federal government and groups of
states have an array of lawsuits and investigations into Big Tech
companies. The FTC has sued Facebook and is investigating Amazon.
The Justice Department has sued Google.
In 2017, she wrote a highly regarded article, "Amazon's Antitrust
Paradox," for the Yale Law Journal which argued that the traditional
antitrust focus on price was inadequate to identify antitrust harms
done by Amazon.
The FTC also assesses pharmaceutical mergers to ensure they are
legal under antitrust law.
(Reporting by Diane Bartz and Eric Beech; Editing by Leslie Adler,
Richard Chang and Cynthia Osterman)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|